BAG5

protein-coding

BAG cochaperone 5, the group of BAG cochaperones

Gene summary

The protein encoded by this gene is a member of the BAG1-related protein family. BAG1 is an anti-apoptotic protein that functions through interactions with a variety of cell apoptosis and growth related proteins including BCL-2, Raf-protein kinase, steroid hormone receptors, growth factor receptors and members of the heat shock protein 70 kDa family. This protein contains a BAG domain near the C-terminus, which could bind and inhibit the chaperone activity of Hsc70/Hsp70. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

MANE transcript

NM_001015048.3

Inheritance

AR

ClinVar variants

P:5U:62B:7

Top phenotype

Cardiomyopathy, dilated, 2F

gnomAD constraint

pLI —, LoF o/e 0.7

Max pathogenic AF

—

Genomic locus

chr14:103,556,545-103,562,657

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~6.1 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

cardiomyopathy, dilated, 2FMODERATE

Inheritance Pattern: AR

Disease ID:MONDO:0030680

Submitter: Ambry Genetics

cardiomyopathy, dilated, 2FSTRONG

Inheritance Pattern: AR

Disease ID:MONDO:0030680

Submitter: Labcorp Genetics (formerly Invitae)

cardiomyopathy, dilated, 2FMODERATE

Inheritance Pattern: AR

Disease ID:MONDO:0030680

Submitter: ClinGen

BAG5 was evaluated for autosomal recessive dilated cardiomyopathy (DCM). BAG5, first described in 1999 (Takayama et al., 1999, PMID: 9873016), is a part of the BAG family of co-chaperones for Hsp70 and Hsc70 aiding in protein folding and trafficking regulation. At the time of review, dilated cardiomyopathy is the only condition that has been associated with this gene. Human genetic evidence supporting this gene-disease relationship includes case-level data. At least 5 variants (nonsense, frameshift) have been reported in humans with DCM in a homozygous or compound heterozygous state. A total of 12 cases across 5 primary publications were reviewed. Two publications from Hakui et al. (Hakui et al., 2022, PMID: 35044787; Hakui et al., 2022, PMID: 36130910) detail 6 of the total reported cases reviewed. In addition, the BAG5 p.Arg197Ter variant first detailed in Hakui et al. 2022 was reported in 6 of the 12 cases reviewed across 3 primary publications in either a homozygous (Hakui et al., 2022, PMID: 35044787; Hakui et al., 2022, PMID: 36130910) or compound heterozygous state (Inoue et al., 2023, PMID: 37873655). While consanguinity was unknown for the homozygous cases, 3 of these cases were identified querying 536 DCM patients in an in-house Japanese database after transcriptomics identified BAG5 as an upregulated gene in tissue from DCM patients compared to controls (Hakui et al, 2022, PMID: 35044787). Frequency of this variant in a small, geographically isolated population suggests a possible founder variant. BAG5 loss-of-function variants were identified in remaining DCM proband cases via whole exome (Inoue et al., 2023, PMID: 37873655; Hakui et al., 2022, PMID 36130910; Wongwong et al., 2024, PMID: 38796549) or whole genome sequencing (Lesurf et al., 2022, PMID: 3588587). While majority of the 12 cases reviewed were from independent families, Wongwong et al., 2024 detailed clinical and genetic evidence from a large, consanguineous, Middle Eastern kindred with whole exome sequencing in 3 affected siblings and 2 unaffected parents, identifying a frameshift BAG5 variant consistent with biallelic loss-of-function. Sanger sequencing in nine additional relatives showed segregation of the variant with normal clinical phenotypes in a heterozygous or wild-type state (Wongwong et al., 2024, PMID: 38796549). In addition, this gene-disease assertion is supported by recapitulated disease phenotypes in animal models with phenotypic rescue, and functional data supporting protein-interaction with a previously curated, moderate-DCM gene, JPH2. Knock-in (KI) homozygous mice harboring the previously detailed p.Arg197Ter variant were created utilizing CRISPR-CAS9 methodology (Hakui et al., 2022, PMID: 35044787). Cardiac phenotypes of homozygous KI-mice were compared to wild-type mice via cardiac magnetic resonance imaging at 12 weeks and echocardiogram imaging from 5 to 12 weeks, identifying a phenotype consistent with DCM. Phenotypic rescue after administration of AAV9 vector carrying wild-type BAG5 and cardiac troponin T promoter (administered at 10 weeks) was successfully demonstrated with significant improvements in left ventricular diastolic diameter (reduction) and fractional shortening (increase) via echocardiogram at 12 weeks of age. Finally, a series of co-immunoprecipitations with HEK239T cells (harboring a different human variant, p.Arg390Ter) and isolated cardiomyocytes from the previously described mouse-model were completed to investigate interaction of specific substrates with the HSC70/BAG5 complex (Hakui et al., 2022, PMID 35044787). Utilizing primary HSC70 antibodies, co-IP experiments with wild-type and mutant HEK293T cells and co-IP experiments with wild-type and mutant isolated cardiomyocytes from the KI-mice model indicated reduced pull down of HSC70 and reduced pull down of JPH2 when mutant BAG5 was present. This data supports indirect interaction of BAG5 with JPH2 through the HSC70/BAG5 complex. In summary, there is moderate evidence to support this gene-disease relationship. More evidence is needed to establish the relationship of BAG5 with AR-DCM definitively. This classification was approved by the ClinGen Dilated Cardiomyopathy Working Group on 6/14/2024 (SOP Version 10).

cardiomyopathy, dilated, 2FSTRONG

Inheritance Pattern: AR

Disease ID:MONDO:0030680

Submitter: PanelApp Australia

Clinical Genomic Database (CGD)

Cardiomyopathy, dilated, 2FAR

Manifestation: Cardiovascular

Intervention: Cardiovascular

Rationale: The condition can involve cardiomyopathy and arrhythmia, and surveillance (eg, with echocardiogram and electocardiogram) may allow early detection and management (eg, the use of LVAD has been described) of manifestations, which may be beneficial

Refs: 35044787; 36130910Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to BAG5 variants in ClinVar

6 Conditions Cataloged
Inborn genetic diseasesTotal: 70
not providedTotal: 5
Cardiomyopathy, dilated, 2FTotal: 5
CardiomyopathyTotal: 1
not specifiedTotal: 1
BAG5-related conditionTotal: 1

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_001015048.3. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
3
clinvar
3
missense
60
clinvar
4
clinvar
64
nonsense
1
clinvar
1
clinvar
2
start loss
0
frameshift
1
clinvar
2
clinvar
2
clinvar
5
splice donor/acceptor (+/-2bp)
0
Total23627074

Highest pathogenic variant AF is 0.00001504928

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 14 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_001015048.3RefSeqNP_001015048.11MANE Select
ENST00000299204.6EnsemblENSP00000299204.41MANE Select
NM_001015049.5RefSeqNP_001015049.21Standard
NM_004873.4RefSeqNP_004864.11Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Regulation of HSF1-mediated heat shock response
  • Cellular responses to stress
  • Cellular responses to external stimuli
  • Cellular response to heat stress

Biological Process

  • protein folding
  • Golgi organization
  • negative regulation of neuron projection development
  • negative regulation of protein ubiquitination
  • negative regulation of proteasomal ubiquitin-dependent protein catabolic process

Molecular Function

  • adenyl-nucleotide exchange factor activity
  • protein binding
  • protein kinase binding
  • ubiquitin protein ligase binding
  • chaperone binding

Cellular Component

  • nucleus
  • mitochondrion
  • cytosol
  • membrane
  • inclusion body

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000337322
Coding exons
2
Length
6288
Individuals with no LoFs
125708
Homozygous LoFs
0
Heterozygous LoFs
40
Defined
125748
p
0.000159
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense0.3722402570.9350.00001463229
Missense (PolyPhen)6982.8030.83331120
Synonymous-0.07671041031.010.00000621931
Loss of Function1.101115.70.7008.36e-7208

Population LoF Frequency

PopulationCAFp-valueStatus
African0.000250.00025rare
Latino/Admixed American0.000120.00012rare
Ashkenazi Jewish00.0absent
East Asian0.000330.00033rare
Finnish0.0000940.000092rare
European (Non-Finnish)0.000160.00016rare
South Asian0.000200.00020rare
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Inhibits both auto-ubiquitination of PRKN and ubiquitination of target proteins by PRKN (By similarity). May function as a nucleotide exchange factor for HSP/HSP70, promoting ADP release, and activating Hsp70-mediated refolding. {ECO:0000250, ECO:0000269|PubMed:20223214}.;

Recessive Scores

pRec
0.204

Intolerance Scores

LoFtool
0.185
RVIS EVS
-0.07
RVIS percentile EVS
48.54

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
0.756

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.